Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression.

Area of Science:

• Neuroscience
• Genetics
• Psychiatry

Background:

• Major depressive disorder (MDD) is a prevalent psychiatric condition.
• Electroconvulsive therapy (ECT) is an effective treatment for severe MDD.
• Identifying genetic predictors of ECT response can personalize treatment.

Purpose of the Study:

• To investigate the association between TPH1 A218C and GNB3 C825T polymorphisms and ECT treatment response in MDD patients.
• To explore if these genetic variations influence susceptibility to MDD or treatment resistance.

Main Methods:

• Case-control study design.
• Genotyping of TPH1 A218C and GNB3 C825T polymorphisms.
• Comparison of genotype frequencies between MDD patients and healthy controls, and analysis of treatment response.

Main Results:

• Neither TPH1 nor GNB3 polymorphisms were significantly associated with ECT treatment response.
• TPH1 CC genotype was more frequent in the patient group than in controls.
• In female subjects, the GNB3 T-allele was associated with increased risk of treatment resistance.
• In females, the combined TPH1 CC and GNB3 CT/TT genotypes increased the risk of belonging to the patient group.

Conclusions:

• TPH1 and GNB3 polymorphisms are not direct predictors of ECT treatment response.
• TPH1 CC genotype may be associated with MDD susceptibility.
• Specific GNB3 genotypes, particularly in combination with TPH1 CC, may confer increased risk for treatment-resistant MDD in females.